Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb prophylactic study of intranasal REVTx-99 in an H3N2 influenza challenge model
2021-003463-97Phase 2Completed
- Sponsor
- Revelation Biosciences
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Influenza A infection and influenza comparing REVTx-99 prophylaxis with Placebo control (2 arms). Primary endpoint: Area under the curve of viral load by RT-qPCR from nasopharyngeal swabs. Started Aug 2021; status: completed.
02
Drugs
Gemini
03
Conditions
Influenza A infectioninfluenza
Beyond the preview
Go deeper on 2021-003463-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003463-97.